MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$263,712K
Net Income
-$637K
Net Profit Margin
-0.24%
Unit: Thousand (K) dollars
Revenue Breakdown
US
Non Us
Revenue Breakdown
Molecular Profiling Services
Pharma Research And Development ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
263,712
216,174
214,687*
216,833
Cost of services-Molecular Profiling Services
81,328
72,884
67,305*
66,980
Cost of services-Pharma Research And Development Services
2,788
1,942
-
-
Selling and marketing expense
53,764
45,043
42,216*
41,267
General and administrative expense (see note 9)
66,548
59,708
50,455*
51,973
Research and development expense
32,358
31,315
31,578*
21,624
Total costs and operating expenses
236,786
210,892
191,553*
184,191
Income (loss) from operations
26,926
5,282
23,134*
32,642
Interest income
6,819
6,834
3,030*
7,360
Interest expense
9,228
12,809
7,781*
13,507
Changes in fair value of financial instruments
0
0
-22,358*
-2,081
Other expense, net
-25,131
49
7,085*
-89
Total other expense, net
-27,540
-5,926
-20,024*
-8,317
Gain before income taxes and income tax benefit
-614
-644
3,110*
24,325
Income tax benefit (expense)
23
-134
0*
0
Net gain
-637
-510
3,110*
24,325
Deemed dividend from series d redeemable convertible preferred stock
0
-
-192,218*
0
Adjustments of redeemable convertible preferred stock to redemption value
0
0
-6,023*
0
Net gain attributable to common shareholders basic
-637
-510
201,351
24,325
Net gain attributable to common shareholders diluted
-637
-510
201,351
24,325
Basic EPS
0
0
1.204
0.09
Diluted EPS
0
0
1.204
0.08
Basic Average Shares
282,888,610
282,562,013
167,205,616*
282,099,073
Diluted Average Shares
282,888,610
282,562,013
167,205,616*
297,211,838
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net gain
attributable to common...
-$637K
(99.88%↑ Y/Y)
Net gain
attributable to common...
-$637K
(99.88%↑ Y/Y)
US
$261,572K
(46.80%↑ Y/Y)
Non Us
$2,140K
(-33.56%↓ Y/Y)
Net gain
-$637K
(99.11%↑ Y/Y)
Total revenue
$263,712K
(45.38%↑ Y/Y)
Gain before income
taxes and income tax...
-$614K
(99.14%↑ Y/Y)
Income tax benefit
(expense)
$23K
Income (loss) from
operations
$26,926K
(249.68%↑ Y/Y)
Total costs and
operating expenses
$236,786K
(18.76%↑ Y/Y)
Total other expense,
net
-$27,540K
(48.81%↑ Y/Y)
Interest income
$6,819K
(321.45%↑ Y/Y)
Cost of
services-Molecular Profiling...
$81,328K
(24.51%↑ Y/Y)
General and
administrative expense (see...
$66,548K
(3.39%↑ Y/Y)
Selling and marketing
expense
$53,764K
(27.22%↑ Y/Y)
Research and development
expense
$32,358K
(29.19%↑ Y/Y)
Cost of
services-Pharma Research And...
$2,788K
(16.56%↑ Y/Y)
Other expense, net
-$25,131K
(-37.02%↓ Y/Y)
Interest expense
$9,228K
(-51.96%↓ Y/Y)
Buy us a coffee
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)